Drug Trial Radar · NCT01619085
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Mar 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
752
Actual
Start
Jun 6, 2012
Primary completion
Jul 5, 2017
Study completion Feb 1, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
NintedanibDrug
Nintedanib twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From first drug administration until end of treatment period + 28 days, in total up to 56.3 months plus 28 days.
Locations
173 sites in 24 countries. Site status is shown where the registry gives one.
Jasper Summit Research, LLC
Jasper, Alabama
Pulmonary Associates
Phoenix, Arizona
University of California
Los Angeles, California
University of California
San Francisco, California
Sansum Clinic
Santa Barbara, California
Stanford University Medical Center
Stanford, California
University of California
Torrance, California
Western Connecticut Medical Group
Danbury, Connecticut
Pulmonary Assoc of Stamford
Stamford, Connecticut
Cleveland Clinic
Weston, Florida
Georgia Clinical Research
Austell, Georgia
University of Chicago
Chicago, Illinois
Via Christi Clinic, PA
Wichita, Kansas
Baptist Health Lexington
Lexington, Kentucky
Minnesota Lung Center
Minneapolis, Minnesota
The Lung Research Center, LLC
Chesterfield, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Pulmonary and Critical Care Associates
Albany, New York
Jamaica Hospital Medical Center
Jamaica, New York
New York Presbyterian Hospital
New York, New York
University of Cincinnati
Cincinnati, Ohio
ID Clinical Research, LTD
Toledo, Ohio
The Oregon Clinic
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
FDC Seifer PLC Pulmonary
Shelbyville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
DCOL Center for Clinical Research
Longview, Texas
Metroplex Pul and Sleep Ctr
McKinney, Texas
Diagnostics Research Group
San Antonio, Texas
Vermont Lung Center
Colchester, Vermont
Inova Fairfax Hospital
Falls Church, Virginia
Lynchburg Pulmonary Associates
Lynchburg, Virginia
University of Wisconsin
Madison, Wisconsin
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Repatriation General Hospital
Concord, New South Wales, Australia
Frankston Hospital
Frankston, Victoria, Australia
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.